Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Payables (2022 - 2026)

HeartSciences filings provide 5 years of Payables readings, the most recent being $3.5 million for Q1 2026.

  • On a quarterly basis, Payables rose 19.76% to $3.5 million in Q1 2026 year-over-year; TTM through Jan 2026 was $3.5 million, a 19.76% increase, with the full-year FY2025 number at $2.9 million, up 202.67% from a year prior.
  • Payables hit $3.5 million in Q1 2026 for HeartSciences, up from $817390.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $3.5 million in Q1 2026 to a low of $396506.0 in Q3 2024.
  • Median Payables over the past 5 years was $1.5 million (2023), compared with a mean of $1.7 million.
  • The widest YoY moves for Payables: up 360.11% in 2025, down 69.08% in 2025.
  • HeartSciences' Payables stood at $1.9 million in 2022, then soared by 30.13% to $2.5 million in 2023, then rose by 5.52% to $2.6 million in 2024, then plummeted by 69.08% to $817390.0 in 2025, then surged by 329.47% to $3.5 million in 2026.
  • The last three reported values for Payables were $3.5 million (Q1 2026), $817390.0 (Q4 2025), and $1.8 million (Q3 2025) per Business Quant data.